Back to results
US 2023/0023726 A1Published application
Pharmaceutical composition comprising peptide that inhibits interaction of p53 and foxo4
AssigneeSupadelixir Inc.
InventorsJang-Hee HAHN, Min-Seo KIM
Life of this patent
Estimating the term…
Abstract
Provided is a method for preventing, ameliorating, or treating degenerative diseases caused by cellular senescence, preferably osteoarthritis or atherosclerosis, comprising a specific peptide as an active ingredient, where the peptide remarkably inhibits the interaction of p53 and FOXO4 (Forkhead box protein O4), thereby inhibiting the expression of a cellular senescence regulator.
Claims4
A method for preventing, improving or treating a degenerative disease caused by cellular senescence, comprising a peptide consisting of three amino acids of the following Formula 1 as an active ingredient:
- Leu-X-Asp <Formula 1>
- wherein,
- X is glutamic acid (Glu), serine (Ser), glycine (Gly), alanine (Ala), glutamine (Gln), arginine (Arg), lysine (Lys), leucine (Leu), tyrosine (Tyr), aspartic acid (Asp), phenylalanine (Phe), asparagine (Asn), cysteine (Cys), histidine (His), isoleucine (Ile), methionine (Met), proline (Pro), threonine (Thr), tryptophan (Trp) , or valine (Val), and
- is a peptide bond.
1 more element
Dependencies are inferred from the claim text.